Chemical Properties:
Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement. Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.Manufacturer Supply; High Quality and Competitive Price Commercial Supply Ezetimibe (CAS: 163222-33-1) Related Intermediates: (S)-(+)-4-Phenyl-2-oxazolidinone CAS: 99395-88-7 (R)-(+)-2-Methyl-CBS-oxazaborolidine CAS: 112022-83-0 4-(4-Fluorobenzoyl)butyric acid CAS: 149437-76-3 4-[[(4-Fluorophenyl)imino]methyl]-phenol CAS: 3382-63-6 N-(4-(Benzyloxy)benzylidene)-4-fluoroaniline CAS: 70627-52-0 (3R,4S)-4-[4-(Benzyloxy)phenyl]-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-oxopropyl]azetidin-2-one CAS: 190595-65-4 (4S)-3-[5-(4-Fluorophenyl)-1,5-dioxopenyl]-4-phenyl-2-oxazolidinone CAS: 189028-93-1 (4S)-3-[(5S)-5-(4-Fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-1,3-oxazolidin-2-one CAS: 189028-95-3 Ezetimibe CAS: 163222-33-1| Item | Specifications |
| Appearance | Off-White to White Powder |
| Purity / Analysis Method | ≥99.0% (HPLC) |
| Loss on Drying | ≤0.50% |
| Single Impurity | ≤0.50% |
| Total Impurities | ≤1.0% |
| Heavy Metals | ≤20ppm |
| Test Standard | Enterprise Standard |
| Usage | Ezetimibe (CAS: 163222-33-1) Intermediate |
Description:
Specifications:
Package & Storage:
| Chemical Name | 4-[[(4-Fluorophenyl)imino]methyl]-phenol |
| CAS Number | 3382-63-6 |
| CAT Number | RF-PI145 |
| Stock Status | In Stock, Production Scale Up to Tons |
| Molecular Formula | C13H10FNO |
| Molecular Weight | 215.22 |
| Melting Point | 179.0 to 183.0℃ |
| Brand | Ruifu Chemical |
Advantages:
FAQ:
Application:
Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of 4-[[(4-Fluorophenyl)imino]methyl]-phenol (CAS: 3382-63-6) with high quality, it is an intermediate of Ezetimibe (CAS: 163222-33-1). Ezetimibe is ananti-hyperlipidemic drug used for lowering the plasma cholesterol levels. Ezetimibe is a cholesterol transport inhibitor that binds to NPC1L1. It is indicated as an adjunctive therapy to diet for the reduction of high-level total-C, LDL-C, and ApoB in patients suffering primary (heterozygous familial and non-familial) hypercholesterolemia.
